Clobazam Dosing in Children
For children aged 2 years or older with seizures (particularly Lennox-Gastaut syndrome), start clobazam at 5 mg/day for children ≤30 kg or 10 mg/day for children >30 kg, titrate weekly to target doses of 20 mg/day and 40 mg/day respectively, administered in two divided doses for amounts exceeding 5 mg/day. 1
Weight-Based Dosing Algorithm
The FDA-approved dosing is stratified by body weight and follows a structured weekly titration schedule 1:
For Children ≤30 kg:
- Day 1-6: 5 mg once daily
- Day 7-13: 10 mg/day (divided into two doses)
- Day 14 onward: 20 mg/day (divided into two doses)
For Children >30 kg:
- Day 1-6: 10 mg once daily
- Day 7-13: 20 mg/day (divided into two doses)
- Day 14 onward: 40 mg/day (divided into two doses)
Do not escalate doses more rapidly than weekly intervals, as clobazam requires 5 days and its active metabolite N-desmethylclobazam requires 9 days to reach steady-state concentrations 1.
Administration Considerations
Oral Suspension Preparation:
- Shake the suspension well before each administration 1
- Use only the provided oral dosing syringe (not household spoons)
- Can be administered with or without food 1
- Insert syringe into bottle, withdraw prescribed dose slowly, then squirt into corner of patient's mouth
Dose Division:
- Single daily dosing is acceptable only for the 5 mg/day dose
- All doses >5 mg/day must be divided into twice-daily administration 1
Special Population Adjustments
CYP2C19 Poor Metabolizers:
If the child is a known CYP2C19 poor metabolizer, reduce all target doses by 50% 1, 2:
- Start at 5 mg/day regardless of weight
- Titrate to maximum of 10 mg/day (≤30 kg) or 20 mg/day (>30 kg)
- Poor metabolizers accumulate the active metabolite N-desmethylclobazam, increasing toxicity risk 2
Hepatic Impairment:
For mild-to-moderate hepatic impairment, use the same dose reduction strategy as for CYP2C19 poor metabolizers 1. Clobazam is not studied in severe hepatic impairment.
Discontinuation Protocol
Never abruptly stop clobazam due to risk of withdrawal seizures and status epilepticus. 1
Taper by decreasing total daily dose by 5-10 mg/day on a weekly basis until discontinued 1. If withdrawal symptoms emerge (increased seizure frequency, anxiety, tremor), pause the taper or increase back to the previous dose level, then resume tapering more slowly.
Efficacy Data
Real-world and clinical trial data demonstrate dose-dependent efficacy 3, 4:
- At 0.25 mg/kg/day: 41% reduction in drop seizures
- At 0.5 mg/kg/day: 49% reduction in drop seizures
- At 1.0 mg/kg/day: 68% reduction in drop seizures
Response rates (≥50% seizure reduction) in pediatric refractory epilepsy range from 58-78% depending on dose 5, 3. Approximately 28-35% of children may achieve complete seizure freedom 5, 6.
Monitoring and Safety
Common Adverse Effects:
- Somnolence/sedation (most common, 14.6%) 5, 3
- Behavioral changes/irritability (7.7%) 5, 7
- Pyrexia, lethargy, drooling 1, 3
Critical Safety Warnings:
- Respiratory depression risk when combined with opioids—reserve combination only when no alternatives exist 1
- Serious dermatological reactions including Stevens-Johnson syndrome—discontinue immediately if rash develops 1
- Monitor for suicidal ideation, particularly in adolescents 1
Tolerance Development:
Unlike other benzodiazepines, clobazam demonstrates sustained efficacy in most patients, with 85% maintaining response beyond one year 7. This distinguishes it from 1,4-benzodiazepines and supports its role as maintenance therapy rather than intermittent use.
Clinical Context
The evidence provided about influenza antivirals (amantadine, rimantadine, oseltamivir, zanamivir) 8, 9, 8, 9, 10, 11 and emergency medications 12, 13 is not relevant to clobazam dosing and should be disregarded. The FDA drug label 1 provides the definitive dosing guidance, supported by pivotal trials in Lennox-Gastaut syndrome 3, 4 and real-world pediatric epilepsy cohorts 5, 6, 7.